טוען...
Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone
PURPOSE OF REVIEW: Giant cell tumor of bone (GCTB) is an uncommon benign primary bone tumor, consisting of receptor activator of nuclear factor kappa-B (RANK) expressing reactive osteoclast-like giant cells and neoplastic spindle-shaped cells. Denosumab was approved by FDA in 2013 and by EMA in 2014...
שמור ב:
| הוצא לאור ב: | Curr Opin Oncol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Lippincott Williams & Wilkins
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6613724/ https://ncbi.nlm.nih.gov/pubmed/30844887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCO.0000000000000529 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|